Organon & Co. OGN
Organon & Co. (NYSE: OGN) is an endocrine/women's health drug developer. Its lead program, Nexplanon (etonogestrel implant), is in Phase 3 for contraception. Its next catalyst on record is Miudella: US commercial launch (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Miudella — US commercial launch (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Nexplanon (etonogestrel implant) | contraception (5-year duration of use approved Jan 2026; EU/UK review pending) | small molecule | Approved |
| NuvaRing | contraception | small molecule | Approved |
| Follistim AQ (follitropin beta) | fertility / assisted reproduction | protein/peptide | Approved |
| Bildyos / Bilprevda (denosumab biosimilars) | osteoporosis / skeletal-related events | antibody | Approved |
| Poherdy (pertuzumab-dpzb) | HER2-positive breast cancer (biosimilar) | antibody | Approved |
| Miudella (copper IUD, in-licensed from Sebela) | contraception | device-combination | Approved |
| Mercilon (desogestrel/EE) | dysmenorrhea (Japan submission) | small molecule | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.